Evaluation of PRRSv specific, maternally derived and induced immune response in Ingelvac PRRSFLEX EU vaccinated piglets in the presence of maternally transferred immunity

PLoS One. 2019 Oct 2;14(10):e0223060. doi: 10.1371/journal.pone.0223060. eCollection 2019.

Abstract

In this study, we analyzed PRRS virus (PRRSv) specific lymphocyte function in piglets vaccinated with Ingelvac PRRSFLEX EU® at two and three weeks of age in the presence of homologous maternal immunity. Complete analysis of maternal immunity to PRRSv was evaluated postpartum, as well as passive transfer of antibodies and T cells to the piglet through colostrum intake and before and after challenge with a heterologous PRRSv at ten weeks of age. Maternal-derived antibodies were detected in piglets but declined quickly after weaning. However, vaccinated animals restored PRRSv-specific antibody levels by anamnestic response to vaccination. Cell analysis in colostrum and milk revealed presence of PRRSv-specific immune cells at suckling with higher concentrations found in colostrum than in milk. In addition, colostrum and milk contained PRRSv-specific IgA and IgG that may contribute to protection of newborn piglets. Despite the presence of PRRSv-specific Peripheral Blood Mononuclear cells (PBMCs) in colostrum and milk, no PRRSv-specific cells could be detected from blood of the piglets at one or two weeks of life. Nevertheless, cellular immunity was detectable in pre-challenged piglets up to 7 weeks after vaccination while the non-vaccinated control group showed no interferon (IFN) γ response to PRRSv stimulation. After challenge, all piglets developed a PRRSv-specific IFNγ-response, which was more robust at significantly higher levels in vaccinated animals compared to the primary response to PRRSv in non-vaccinated animals. Cytokine analysis in the lung lumen showed a reduction of pro-inflammatory responses to PRRSv challenge in vaccinated animals, especially reduced interferon (IFN) α levels. In conclusion, vaccination of maternally positive piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX EU induced a humoral and cellular immune response to PRRSv and provided protection against virulent, heterologous PRRSv challenge.

MeSH terms

  • Animals
  • Animals, Newborn
  • Antibodies, Viral / immunology
  • Antibody Formation / immunology
  • Bronchoalveolar Lavage Fluid / virology
  • Colostrum / cytology
  • Cytokines / metabolism
  • Female
  • Immunity, Cellular
  • Immunity, Humoral
  • Immunity, Maternally-Acquired*
  • Immunoglobulin A / immunology
  • Immunoglobulin G / immunology
  • Inflammation Mediators / metabolism
  • Interferon-gamma / metabolism
  • Lung / pathology
  • Milk / cytology
  • Porcine respiratory and reproductive syndrome virus / immunology*
  • Species Specificity
  • Swine
  • Vaccination*
  • Viremia / immunology
  • Viremia / virology

Substances

  • Antibodies, Viral
  • Cytokines
  • Immunoglobulin A
  • Immunoglobulin G
  • Inflammation Mediators
  • Interferon-gamma

Associated data

  • Dryad/10.5061/dryad.6hn8db1

Grants and funding

Boehringer Ingelheim Vetmedica GmbH funded the study. The funder provided support in the form of salaries for authors [all], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.